Byondis to Profile Potential of Platform Technologies at World ADC San Diego, Advancing Strategy to Lead the Antibody-Drug Conjugate Field
NIJMEGEN, The Netherlands – 7 October 2026 – Byondis B.V., a private biopharmaceutical company engineering antibody-drug conjugates (ADCs) to tackle the cancers that current therapies cannot reach, will share progress from its platform technology portfolio at World ADC San Diego, the world's largest ADC conference, bei…
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Résiliable à tout moment · 99 $ CA/mois


